Argireline (Acetyl Hexapeptide-3)

Also known as: Acetyl hexapeptide-3, Acetyl hexapeptide-8

Argireline (acetyl hexapeptide-3/8) is a synthetic peptide designed to mimic the N-terminal domain of SNAP-25, a component of the SNARE complex essential for vesicle fusion. By competitively binding to the SNARE complex, it partially inhibits the release of acetylcholine at the neuromuscular junction, thereby reducing muscle contraction intensity. This mechanism is analogous to botulinum toxin but with significantly lower potency and no enzymatic activity, resulting in a reversible, mild relaxation of facial muscles that softens expression lines—hence its colloquial designation as "topical Botox." Despite widespread commercial use in cosmetics, published peer-reviewed research on Argireline remains limited. No indexed studies in PubMed directly investigate its efficacy or safety in human subjects. Available data derive primarily from in vitro models and manufacturer-sponsored trials, which suggest a reduction in wrinkle depth after topical application. However, independent replication and rigorous clinical validation are lacking, and the peptide's ability to penetrate the stratum corneum in sufficient concentrations to exert a measurable pharmacological effect is debated. Clinically, Argireline is marketed as a cosmetic ingredient for temporary improvement of periorbital and forehead wrinkles. Its regulatory status varies by jurisdiction; in the U.S., it is not classified as a drug but as a cosmetic additive, exempt from FDA premarket approval. Given the absence of robust clinical evidence and the experimental nature of its proposed mechanism, its use should be approached with caution. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides